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Abstract
Hypnosis is a therapeutic technique that primarily 
involves attentive receptive concentration. Even though 
a small number of health professionals are trained 
in hypnosis and lingering myths and misconceptions 
assoc ia ted w i th th i s method have hampered 
its widespread use to treat medical conditions, 
hypnotherapy has gained relevance as an effective 
treatment for irritable bowel syndrome not responsive 
to standard care. More recently, a few studies have 
addressed the potential influence of hypnosis on upper 
digestive function and disease. This paper reviews 
the efficacy of hypnosis in the modulation of upper 
digestive motor and secretory function. The present 
evidence of the effectiveness of hypnotherapy as 
a treatment for functional and organic diseases of 
the upper bowel is also summarized, coupled with a 
discussion of potential mechanisms of its therapeutic 
action.
© 2008 The WJG Press. All rights reserved.
Key words: Hypnosis; Hypnotherapy; Gastric emptying; 
Small bowel transit; Functional dyspepsia; Functional 
esophageal disorders; Functional bowel disorders
Peer reviewers: Asbjørn M Drewes, Professor, Department of 
Medical Gastroenterology, Center for Visceral Biomechanics 
and Pain, Aalborg Hospital, Aalborg 9000, Denmark; Jackie 
Wood, PhD, Department of Physiology and Cell Biology, 
College of Medicine and Public Health, The Ohio State 
University, 304 Hamilton Hall, 1645 Neil Avenue, Columbus, 
Ohio 43210-1218, United States
Chiarioni G, Palsson OS, Whitehead WE. Hypnosis and upper 
digestive function and disease. World J Gastroenterol 2008; 
14(41): 6276-6284  Available from: URL: http://www.wjgnet.
com/1007-9327/14/6276.asp  DOI: http://dx.doi.org/10.3748/
wjg.14.6276
INTRODUCTION
Hypnosis can be def ined as an a l tered state of  
consciousness, different from both sleep and normal 
wakefulness, characterized by highly focused attention 
and heightened compliance with suggestion[1]. As a 
rule, the onset of  this state is facilitated by eye closure. 
A number of  other phenomena are often described as 
associated with hypnosis, including altered perception 
of  passage of  time, partial or complete amnesia for 
the events experienced, and attenuation of  stress 
experiences[1-3]. In addition, subjects may show enhanced 
compliance to suggestion given during hypnosis meant 
to influence favorably their behavior after the trance 
state has been terminated (post-hypnotic suggestion)[1]. 
Furthermore, a more contentious property of  hypnosis 
is either increased access to memories, feelings, and 
perceptions which are normally kept below the level of  
conscious awareness, or vice versa enhanced suppression 
of  these from the conscious mind[4-6]. 
Clinical hypnosis is the method of  deliberately 
inducing the state of  hypnosis in a patient through verbal 
guidance, and making use of  its characteristic properties 
for targeted therapeutic purposes. The possibilities of  
hypnosis as a healing method stem principally from the 
heightened responsiveness to suggestion in this altered 
mental state. Hypnotic and post-hypnotic suggestions 
can be used to facilitate desired therapeutic changes 
in feelings, behavior and physiology, and this can be 
useful not only for mental health purposes, but also in 
medicine[1]. Although a single hypnosis session targeting 
a simple symptom or bodily function can sometimes 
yield useful results, treatment of  complex psychological 
and somatic condit ions with hypnosis typical ly 
requires a structured form of  therapeutic intervention, 
hypnotherapy, administered in a series of  several therapy 
sessions[1].
Hypnosis has a long history of  application as a 
clinical tool in medicine, dating back to the early 18th 
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Century, when it was used with considerable success for 
the purpose of  inducing anesthesia during surgery in 
thousands of  cases, predominantly by British physicians. 
Only the availability of  chemical anesthesia with ether 
and chloroform in 1846 and 1847 made this application 
obsolete[7]. 
In the latter half  of  the 19th century, hypnosis 
became prominently utilized in the treatment of  
psychiatric conditions like hysteria by some of  Europe’s 
foremost authorities in neurology and psychiatry of  
that time, such as Sigmund Freud in Austria and Jean-
Martin Charcot in France[8]. Ever since then, hypnosis 
has been more widely recognized as a treatment aid 
for mental health problems than for physical ailments. 
However, medical uses of  hypnosis continued, and 
sufficient experience with various advantageous medical 
applications gradually accumulated for the technique of  
clinical hypnosis to earn formal acceptance in mainstream 
medicine[7,8]. Hypnosis gained official approval as a medical 
treatment, first by the British Medical Association in 1955 
and then by the American Medical Association in 1958, in 
a report that stated that hypnosis had “definite and proper 
applications in medicine and dentistry”, and recommended 
that physicians should receive training in the technique[7,8]. 
However, even today, most medical school curricula in 
the U.S. and elsewhere provide no training or education in 
hypnosis. Although clinical hypnosis is currently practiced 
by thousands of  health professionals in many Western 
countries, it is practiced by a variety of  professional 
disciplines, including psychologists, counselors, clinical 
social workers, dentists, nurses and nurse practitioners, 
but relatively few physicians[7,8]. In many places, the great 
majority of  practitioners providing hypnosis are mental 
health professionals who rarely use it to treat physical 
conditions. Additionally, hypnosis services are commonly 
offered also by large numbers of  lay hypnotherapists 
without any qualifications or formal education in treating 
medical problems[8]. These limitations, as well as myths, 
misconceptions and apprehensions that still linger in 
the public’s mind from the exploitation and inaccurate 
portrayal of  hypnosis in stage shows, movies and other 
popular media, has continued to hamper a widespread 
proper medical use of  hypnosis.
Nonetheless, several medical applications of  
clinical hypnosis have been sufficiently investigated 
and considered effective in multiple formal studies. A 
review by a 1995 National Institutes of  Health panel 
in the U.S. concluded that there is “strong evidence for 
the use of  hypnosis in alleviating pain associated with 
cancer”[9]. Published systematic reviews of  randomized 
clinical trials have also deemed hypnosis to be effective 
for treating nausea and vomiting associated with 
cancer chemotherapy[10] as well as the most promising 
psychological treatment for controlling procedure-
related pain and distress in children and adolescents[11]. 
Fur thermore, three separate systematic reviews 
published in the past three years[12-14] have concluded that 
hypnotherapy is an effective treatment for irritable bowel 
syndrome. 
Research on the use of  hypnosis for gastrointestinal 
disorders began with a randomized placebo-controlled 
study of  hypnotherapy for treatment-refractory irritable 
bowel syndrome (IBS) in England, published in the 
Lancet in 1984[15]. In this study, by Peter Whorwell and 
colleagues in Manchester, England, the investigators 
randomly allocated 30 patients with IBS which was 
refractory to standard medical care, to either seven 
sessions of  hypnotherapy or to the same amount 
of  supportive psychotherapy plus placebo pills. The 
hypnosis approach used was a structured intervention 
developed by this Manchester team called gut-focused 
hypnotherapy. This technique aims primari ly to 
normalize disordered bowel function, but additionally 
provides relaxation, coping skills, and ego-strengthening 
suggestion[16]. After the treatment, the patients in the 
hypnosis group showed substantial improvement in all 
cardinal IBS symptoms, and were significantly more 
improved on all outcome variables than the supportive 
psychotherapy group[15]. In a later paper, the investigators 
reported that the benefits of  hypnotherapy in the same 
group of  patients persisted up to 18 mo[17]. 
This study, albeit small, was a landmark trial , 
demonstrating for the f irst t ime the substantial 
possibilities that hypnosis offers for ameliorating 
gastrointestinal symptoms. Since then, positive results 
on the efficacy of  hypnotherapy as a treatment for 
IBS have been reported by independent investigators 
both in uncontrolled and controlled trials (Table 1)[18-22]. 
The Manchester group has created a Hypnotherapy 
Unit, where this mode of  therapy is routinely offered 
to functional GI patients who do not gain satisfactory 
benefit from more conventional medical treatment[16]. 
This group recently reported the long-term outcomes of  
the first 250 IBS patients treated in their clinic[22,23]. The 
results show an impressive 71% overall response rate to 
treatment, more than 50% average reduction in bowel 
symptom severity, and with four out of  five treatment 
responders maintaining the full therapeutic benefit for 
one to five years after treatment termination[22,23]. 
The Manchester group has also expanded their 
experience from IBS therapy to other functional 
bowel disorders[16]. They demonstrated that functional 
esophageal disorders and functional gastroduodenal 
disorders are also suitable targets for hypnotherapy, with 
equally satisfactory results (Table 1)[24,25]. A small, but 
significant group of  papers now provides evidence that 
hypnosis and hypnotherapy may effectively influence 
upper digestive function and disease. The aim of  this 
review is to focus on this literature and to highlight the 
potential of  hypnotherapy as a treatment option for 
upper digestive functional disorders.    
HYPNOSIS AND UPPER DIGESTIVE 
FUNCTION
Gastric acid production is the bowel function where the 
influence of  hypnosis was first investigated[26,27]. In the 
past, gastric acid secretion was an important research 
domain for gastroenterologists and its responsiveness to 
emotions and psychological stress were documented[28,29]. 
This interest was driven by the belief  that peptic ulcer 
disease was a psychosomatic disease, and excess gastric 
acid secretion the pathophysiological mechanism 
linking emotion to the disease[30,31]. As a consequence, 
acid secretion was an attractive parameter to attempt 
to influence by hypnosis. A few studies were published 
in the nineteen sixties and early seventies examining 
the gastric secretory responses to hypnotic conditions, 
where either food-related (hunger-eating) or emotion-
related (sleep-relaxation) suggestions were provided[27-29]. 
These early studies were flawed by small samples and 
questionable research methodology, and produced 
contradictory results. In 1989, however, Klein and Spiegel 
published a well-designed trial investigating the ability 
of  hypnosis to modulate gastric acid secretion in highly 
hypnotizable healthy volunteers, as defined by accepted 
scales of  trance depth[32]. The study was conducted in 
two centers, by two experienced hypnotherapists using 
two different hypnosis induction techniques. After naso-
gastric intubation, gastric secretion was measured both 
basally and after pentagastrin stimulation in two separate 
studies. In the first study (acid stimulation test), acid 
secretion was collected in 28 subjects (13 females, age 
range 18-60 years) after hypnotic instructions to visualize 
and eat the most delicious meal possible. All the sensory 
aspects of  the eating process, including food appearance, 
aroma, texture and taste, were explored and reinforced 
by hypnotic suggestions from the therapist. The second 
study consisted of  two separate sessions that were 
held in random order. In the no-hypnosis session, the 
peak acid output (PAO) was obtained after maximal 
pentagastrin stimulation in 17 subjects (7 females, age 
range 18-60 years), but hypnosis was not provided. The 
procedure for the hypnosis sessions was the same, but 
deep muscle relaxation and intense imagery to divert 
one’s attention from eating were provided. Imagery 
involved either lying on a beach, watching a sunset, 
or meeting a friend somewhere else. In both studies, 
none of  the subjects reported difficulty in following the 
hypnotic suggestion or adverse side effects. Hypnotic 
suggestion of  eating significantly increased gastric acid 
output compared to basal conditions[32]. In addition, the 
pentagastrin-stimulated PAO was significantly lowered 
in the averting-food hypnosis condition compared to 
the no-hypnosis session[32]. The authors concluded that 
gastric acid secretion may be modulated by hypnosis in 
highly hypnotizable subjects. Treatment mechanisms of  
action were left unexplored. But, the authors postulated 
that hypnosis influenced cognitive processing within the 
central nervous system[32]. Since the relevance of  gastric 
secretion in peptic ulcer disease has diminished, no other 
centers have tried to replicate these positive results. 
Two additional studies have evaluated the influence 
of  hypnosis on upper digestive transit. In 1991 Beugerie 
et al studied the ability of  hypnosis to modulate the 
orocaecal transit time of  10 g lactulose in six healthy 
volunteers[33]. Orocaecal transit time was measured by 
the hydrogen breath test. Oral ingestion of  a poorly 
absorbable carbohydrate (lactulose) results in a sustained 
rise in breath hydrogen, which occurs within minutes 
of  the substrate entering the cecum[34]. The orocaecal 
transit time is the interval elapsing from the ingestion of  
the substrate to the evidence of  a persistent increment 
in breath hydrogen concentration[34]. It is commonly 
considered a non-invasive, reliable index of  small bowel 
transit, particularly when lactulose is included in a caloric 
meal to securely interrupt the fasting motility pattern 
of  the small bowel[35]. The subjects in this trial were 
recruited irrespectively to their hypnotizability, but two 
of  them had previously been hypnotized. Orocaecal 
transit was evaluated on three occasions in random 
order: (A) control session without hypnosis; (B) hypnotic 
session with suggestion of  deep relaxation; (C) hypnotic 
session with visualization of  a cascading waterfall to 
promote transit acceleration[33]. All hypnosis sessions 
were started just before orocaecal transit and maintained 
till the transit time elapsed. The mean orocaecal transit 
time was significantly longer during the hypnotic 
relaxation session compared to the control session[33]. On 
the contrary, the hypnotic acceleration session did not 
result in significant modification of  small bowel transit 
time[33]. The small sample size and the limited breath 
technique used (lactulose not administered together with 
a caloric test meal) did flaw the results of  this study. 
However, it was the first study showing an influence of  
hypnosis on upper digestive function in individuals not 
selected for high hypnotizability. 
The potential influence of  hypnosis on gastric 
emptying rates has been evaluated only recently, by 
Chiarioni and coworkers in Italy[36]. In this study, the 
gastric emptying rate of  a typical Mediterranean meal 
Table 1  Randomized controlled trials of hypnosis treatment for severe functional bowel disorders
Authors & yr No. of patients Control treatment Positive outcome Follow-up (mo)
A: Irritable bowel syndrome
     Whorwell et al (1984)   30 Psychotherapy plus Placebo Pill Hypnosis 100% P < 0.0001 12
     Galovski & Blanchard (1998)   11 Waiting List Hypnosis 82% P = 0.016   2
     Palsson et al (2002)   24 Waiting List Hypnosis 87% P = 0.002 10
B: Functional Dyspepsia
     Calvert et al (2002)                126 Psychotherapy plus Placebo Pill or 
Ranitidine 300 mg daily 
Hypnosis 73% vs Placebo P < 0.02 vs 
Ranitidine P < 0.01  
14
C: Non-cardiac chest pain
     Jones et al (2006)   28 Psychotherapy plus Placebo Pill Hypnosis 80% P = 0.008   4 
Note: Randomized controlled studies run in primary care are not reported for different patient population.
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(pasta with meat sauce, cheese, bread) was tested by 
a non-invasive ultrasonography technique. Real-time 
ultrasonography was used to measure the diameters of  
the gastric antrum in the sagittal plane passing through 
the aorta. Serial measurements were taken before the 
meal, immediately after eating and at 30 min intervals 
thereafter to obtain total emptying time of  the meal. 
The total emptying time of  the meal has been validated 
as reliable index of  gastric motor function both in health 
and in disease when compared with total emptying time 
measured by gastric scintigraphy[37]. Gastric emptying 
rates and epigastric sensations were evaluated in 11 
healthy volunteers from the hospital staff  and in 15 
patients with severe functional dyspepsia unresponsive to 
standard care under three conditions according to a fixed 
schedule to avoid a carry-over effect: (A) basal session, 
(B) prokinetic drug session (cisapride 10 mg po 30 min 
before meal), and (C) hypnosis session (90 min hypnosis 
session 30 min after finishing meal). An additional 
session was run in eight healthy volunteers while 
listening to relaxing music, to address the potential 
influence of  both repeated testing and posture. Cisapride 
is a prokinetic agent that has been shown to significantly 
improve both gastric emptying and symptoms in 
functional dyspepsia compared to placebo, before being 
withdrawn from the market for its cardiovascular side-
effects[38,39]. The method of  progressive relaxation by 
verbal suggestion was used for hypnosis induction. 
Techniques to deepen the hypnosis included induction 
of  limb heaviness and warmth. The hypnotically warmed 
hand was then placed over the epigastrium to associate 
suggestion of  improved well being and gastric function 
mediated by the warmth of  the hand. Imagery was 
provided of  water flowing in a river and in a waterfall. 
This was related to suggestions for improved well-being 
and gastric function, derived from the gut-oriented 
suggestions developed by the Manchester group to treat 
irritable bowel syndrome[16]. The hypnosis session was 
completed by the classic Hartland’s ego-strengthening 
technique, providing direct and broad hypnotic 
suggestions to increase the patient’s confidence[40]. In 
patients with functional dyspepsia, gastric emptying was 
significantly shortened by cisapride and even more by 
hypnosis compared to the basal session[36]. In healthy 
volunteers, gastric emptying was significantly accelerated 
by hypnosis, but not by cisapride, compared to the basal 
session[36]. The relaxing music session did not influence 
gastric emptying rates. Epigastric sensations (i.e. fullness 
and discomfort) were significantly improved by hypnosis 
in the dyspeptic patients, but not by cisapride[36]. 
Interestingly, symptomatic improvement did not 
correlate with improved gastric motor function, leaving 
the mechanism/s of  action of  hypnosis unexplained[36]. 
Limitations of  the study were lack of  randomization and 
the highly selected study population. 
HYPNOTHERAPY TO TREAT UPPER 
DIGESTIVE DISEASES
Hypnotherapy delivered as a structured, multi-session 
focused intervention has been most extensively used to 
treat IBS according to the protocols of  the Manchester 
group or the North Carolina group[13,16]. However, 
the Manchester group has also provided experimental 
evidence to support the use of  hypnotherapy in some 
upper digestive diseases. The first of  these was a 
controlled study to prevent relapse of  peptic ulcer[41]. 
The investigation was published in 1988 when peptic 
ulcer was considered to be a psychosomatic disorder 
caused by increased gastric secretion[30,31]. Thirty 
patients with frequently relapsing duodenal ulcer were 
randomized to receive either seven sessions of  gut-
focused hypnotherapy plus ranitidine 150 mg twice daily 
or seven routine consultations at a GI clinic without 
hypnosis plus the same ranitidine dosage over a 10-wk 
interval[41]. Hypnosis was induced with an arm-levitation 
technique followed by a combination of  standard 
deepening procedures. The subject was then asked to 
place her/his hand over the abdomen, feel a sense of  
warm beneath the hand, and relate this to the control of  
gastric secretions. Reinforcement by visualization was 
used depending on the patient’s ability. Patients were 
also given an audio tape for daily autohypnosis. At one 
year follow-up, all the subjects in the no-hypnosis group 
had relapsed while only 53% in the hypnotherapy group 
showed endoscopic evidence of  relapsing duodenal 
ulcer[41]. The authors concluded that hypnotherapy 
is helpful in maintaining remission in those patients 
with peptic ulcer who are prone to relapse[41]. Shortly 
after the study, consensus developed that Helicobacter 
pylori infection of  the stomach is the primary cause of  
peptic ulcer disease, and hypnotherapy was, therefore, 
not pursued further as potential treatment for peptic 
disease[42]. Nonetheless, this remains the first study to 
investigate the efficacy of  hypnotherapy to treat upper 
digestive diseases.
Recently, the Manchester group assessed the efficacy 
of  hypnotherapy for upper digestive functional diseases 
in two controlled trials; one on functional dyspepsia (FD) 
and the other for non-cardiac chest pain (NCCP)[24,25]. 
Functional dyspepsia refers to symptoms thought to 
originate in the gastroduodenal region in the absence of  
any organic or metabolic disease that is likely to explain 
the symptoms[43]. Postprandial fullness, early satiety, 
epigastric pain and/or burning may be reported as 
symptoms in FD[43]. Delayed gastric emptying, abnormal 
gastric tone, altered visceral perception, and autonomic 
imbalance have all been considered as potential etiologic 
factors[43,44]. In addition, comorbidity with psychiatric 
disorders, especially anxiety disorders, is reported to be 
high in FD[45]. Up to 30% of  people in the community 
report having dyspeptic symptoms each year [43,45]. 
Symptomatic drug treatment, especially proton pump 
inhibitor medications, are often used for FD symptoms. 
But, the results are unsatisfactory[43,44,46]. To investigate 
the efficacy of  hypnotherapy in FD, Calvert and 
coworkers randomly assigned 126 FD patients to receive 
either 12 hypnotherapy sessions, supportive therapy plus 
placebo tablets, or medical treatment with ranitidine 
150 mg twice daily [24]. Patients underwent a 16-wk 
www.wjgnet.com
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treatment phase followed by a 40-wk follow-up phase 
where no further study interventions were undertaken. 
Hypnosis was induced using eye fixation followed 
by progressive muscular relaxation and deepened by 
standard procedures. The patients were then asked to 
place their hands on their abdomens and imagine a 
reduction of  all symptoms. Suggestions of  improvement 
in gastric motor function, sensitivity and gut secretion 
activity were also given. Reinforcement by appropriate 
visualization processes were administered as well. At the 
short term follow-up (16 wk), hypnotherapy significantly 
ameliorated symptoms compared to both the supportive 
therapy and the medical treatment groups[25]. Analogous 
improvements were observed when quality of  life 
scores (QOL) were considered. Anxiety scores were 
lower after hypnotherapy; but there was no correlation 
between improvement in anxiety and FD symptom 
improvement[24]. No differences were evident between 
groups in terms of  depression scores. Improvement 
in FD symptoms and QOL were well-maintained at 
long term follow-up (56 wk)[24]. In addition, patients in 
the hypnotherapy group were significantly less likely to 
consult the referring physician and to establish additional 
drug treatments than were the subjects in the other two 
groups[24]. The authors concluded that hypnotherapy is 
an effective treatment for functional dyspepsia both in 
the short and long term, but the mechanism/s of  action 
remained speculative[24]. Hypnotherapy seems also to be 
cost-effective for the observed reduction in medication 
use and consultation rate at long term follow-up. This 
study was methodologically sound by most standards: (A) 
study design and sample size were both adequate, and (B) 
the double placebo control condition plus the standard 
care arm were likely to have produced a high expectation 
of  therapeutic effect. Replication of  these positive 
results by independent investigators is eagerly awaited.
Recently, the Manchester group has extended the 
application of  hypnotherapy to non-cardiac chest 
pain, a condition later redefined as functional chest 
pain of  presumed esophageal origin by the Rome Ⅲ 
Committee [25,47]. This functional disorder refers to 
relapsing episodes of  unexplained chest pain that 
is usually located in the midline of  the chest and of  
visceral quality[47]. The pain involved may be similar in 
nature to the one reported by angina patients, and by 
those affected by other esophageal disorders including 
achalasia and gastro-esophageal reflux disease (GERD)[47]. 
To diagnose functional chest pain, heart disease needs 
to be excluded as well as structural esophageal diseases, 
GERD, and esophageal motility disorders with defined 
histopathologic bases (i.e. achalasia, scleroderma of  the 
esophagus)[47]. Epidemiology of  functional chest pain 
is ill defined; but one should consider that 15%-30% 
of  coronary angiograms performed for chest pain are 
negative for ischemic heart disease[47,48]. Disordered 
esophageal motility, altered visceral perception, and 
abnormal central signal processing with secondary errors 
in autonomic response have all been reported, alone 
or in combination, as potential causative factors[47]. In 
addition, overrepresentation of  psychiatric disorders, 
particularly depression, anxiety and somatization 
disorders, have been described in functional chest pain 
of  presumed esophageal origin[49]. Quality of  life is 
impaired in continued pain and spontaneous recovery is 
rare[47]. In these patients, a therapeutic trial with proton 
pump inhibitors is mandatory to exclude symptomatic 
reflux disease[50]. Antidepressants may be of  help, but 
their continuous use is associated with a high rate of  
side effects[47,51]. 
To address the effect of  hypnotherapy in NCPP, 
the Manchester group randomized 28 patients with 
functional chest pain to receive either 12 sessions 
of  individualized hypnotherapy or 12 sessions of  
supportive listening plus placebo tablets to control 
for expectancy and equalize the amount of  time spent 
with a clinician[25]. All the patients were referred by 
the local cardiothoracic center after negative coronary 
angiography for angina-like chest pain. Reflux disease as 
a potential causative factor of  chest pain was excluded 
in all subjects either by normal 24 h pH monitoring 
or by non-responsiveness to a proton pump inhibitor 
trial. Hypnosis was induced by eye closure, followed by 
progressive muscle relaxation and deepened by standard 
techniques. Suggestions focused on improved esophageal 
functioning and sensitivity were then introduced by using 
both imagery and conditioning techniques. In addition, 
direct suggestions of  reduced pain and improved general 
health were given on a repetitive basis at each session. 
After treatment, 80% of  patients in the hypnotherapy 
group described their chest pain as completely better or 
moderately better, compared to only 23% of  patients in 
the control group[25]. This benefit persisted long-term 
(2 years), as reported by the authors in a follow-up 
paper[52]. Hypnotherapy also resulted in a significantly 
greater reduction in pain intensity scores, greater 
improvements in quality of  life, and a greater reduction 
in medication usage when compared to the control 
treatment [25]. There were no significant differences 
between treatment groups in terms of  improvement of  
either anxiety or depression scores as assessed by the 
Hospital anxiety and depression scale[25]. 
Limitations of  this trial include the small sample size 
and the high patient selection. As in previous studies, the 
mechanism of  action of  hypnosis was left unexplored 
in this study. However, it remains the only randomized 
trial to show that hypnotherapy is effective treatment for 
functional chest pain, a disabling disorder that responds 
poorly to conventional care. Therefore, additional 
larger studies evaluating the effect of  hypnotherapy on 
functional chest pain of  presumed esophageal origin 
should be pursued. 
MECHANISM OF ACTION OF HYPNOSIS 
AND HYPNOTHERAPY
The mechanism of  action of  hypnosis is ill defined; but 
we may speculate that many factors possibly contribute 
to its influence on physiological function and symptoms 
in the upper digestive tract. Abnormal motor activity and 
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altered autonomic function have both been reported in 
functional gastroduodenal and esophageal diseases[43,47]. 
In functional dyspepsia, delayed gastric emptying seems 
particularly common in patients complaining of  nausea, 
fullness and vomiting; but this is controversial[43,53]. 
Other disturbances of  gastroduodenal motility have 
been described in functional dyspepsia (e.g. antral 
hypomotility, gastric dysrhythmia, reduced frequency 
of  interdigestive migrating motor complexes); but their 
relationship to the symptoms is less documented[43]. 
On the contrary, evidence of  increased gastric visceral 
perception (so-called hypersensitivity) in a subset of  
functional dyspepsia patients is well documented in the 
literature[43,54]. This altered perception may be mediated 
by the autonomic imbalance both on a cortical and a 
peripheral level often described in functional bowel 
disorders[55]. Hypnosis induces a state of  profound 
relaxation consistent with a generalized decrement in 
sympathetic nervous system activity[1,3]. This relaxation 
response is not specific to hypnosis, but may be induced 
by different techniques such as autogenic training, yoga, 
and meditation[3]. The physiological changes of  the 
relaxation response include simultaneous lowering of  
blood pressure, heart and respiratory rates, which are 
opposite to those induced by stressful events[3]. These 
changes are actually distinct from those observed during 
sleep and characterize a wakeful hypometabolic state[56]. 
In addition, the relaxation response seems to last longer 
than the actual hypnosis interval[3]. A distinct feature 
of  the relaxation response is that its action seems to be 
mediated through a reduction in epinephrine end-organ 
responsivity[3]. Stress has been shown to increase gastric 
acid secretion, and it used to be considered a risk factor 
to developing peptic ulcer disease[30,57]. We may speculate 
a potential influence of  hypnosis on gastric secretion 
through modulation of  the sympathetic tone. In 
addition, experimental stress delays gastric emptying and 
increases plasma levels of  noradrenaline plus accelerating 
small bowel transit [58-60]. Therefore, the capability 
of  a single session of  hypnosis either to accelerate 
gastric emptying or to slow small bowel transit may be 
secondary to the relaxation response. However, a recent 
study investigating hypnosis mechanisms of  action 
showed that hypnotherapy did not change cardiovascular 
responses in IBS[23]. The only parameter of  sympathetic 
tone that was significantly decreased by hypnotherapy 
was skin conductance, a measure reflecting sweat gland 
responses to stress[23]. 
The effect of  hypnosis in gastric visceral sensitivity 
has not been investigated. However, in IBS the influence 
of  hypnotherapy on rectal perception has been evaluated 
with controversial results. The Manchester group 
provided experimental evidence that hypnosis improved 
rectal sensitivity; but this was not confirmed by a recent 
study by the North Carolina group[23,61]. In addition, one 
should consider that significant symptom improvement 
has been repor ted in functional bowel diseases 
without correlating with gut sensorimotor functioning 
modifications[23,36,12]. Therefore, the symptomatic 
improvement observed after hypnosis should also be 
related to some modulation of  perception at a cortical 
level. Brain imaging studies have shown a variety of  
alterations in cortical activation pattern to visceral 
sensitive stimulation (rectal distension, esophageal 
distension and acid perfusion) in patients with functional 
bowel disorders compared with controls[62]. However, 
a consistent finding has been the reported excessive 
activation of  the anterior cingulated cortex where the 
affective response to pain is elaborated[62]. It has also 
been shown that non-painful esophageal distension 
activated the somatosensory and anterior cingulated 
cortex while visual stimulation activated a different 
central area (visual cortex), thus postulating a more 
specific response to visceral stimulation[63]. Studies on 
somatic pain have shown that hypnosis is capable of  
decreasing reported pain sensation in response to pain-
inducing stimuli, while the neurophysiological reactions 
of  spontaneous and evoked EEG were unaffected (i.e. 
cerebral potentials were modified as the subject was 
actually feeling pain)[64]. Further supporting evidence 
has been given by studies on somatic pain analgesia 
where hypnosis reduced activity of  the anterior cingulate 
cortex, but not that of  the somatosensory cortex[65]. This 
dissociation of  sensory and affective components of  
pain under hypnosis would also be consistent with the 
new “dissociation theory” to explain the effectiveness 
of  hypnotherapy in psychopathology[1,8,66]. There is 
growing evidence that patients with IBS, functional 
chest pain and probably functional dyspepsia show 
increased levels of  vigilance toward gut pain related 
sensations, easily interpreting them as symptoms 
of  disease as a consequence[62,67,68]. Modulating the 
affective component of  pain ratings may be one of  the 
therapeutic mechanisms of  hypnotherapy in functional 
bowel disease. 
An additional reason for the effectiveness of  
hypnotherapy in functional bowel diseases could be 
related to the focus of  many protocols on reducing the 
catastrophising cognitions commonly present in these 
patients[67,68]. Gonsalkorale and coworkers reported that 
hypnotherapy improved symptom-related cognitions in 
IBS by using a dedicated cognitive scale[69]. In this study, 
improved cognitive scores correlated with symptomatic 
improvement[69]. Finally, the role of  the placebo effect 
of  hypnotherapy needs to be considered in producing 
the beneficial hypnotherapy outcomes observed. In 
many hypnotherapy trials patients affected by severe, 
unremitting symptoms of  functional bowel disorder have 
been included[13,24,25,36]. The motivation to undergo a new 
treatment and therapy expectancy in these patients are 
predicted to be high[70]. In addition, the most powerful 
placebo effect is to be expected in patients suffering 
from chronic pain syndromes[70]. In this context, the 
placebo effect is stronger when complex interventions 
such as hypnotherapy are provided[70]. Unfortunately, to 
undertake a double blind controlled trial of  treatments 
such as hypnotherapy is almost impossible because 
the recipient will know what treatment is provided and 
establishing a sham hypnosis therapy is not doable[16]. 
Therefore, appropriate control treatments (e.g. supportive 
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listening and placebo pills) are desirable options when 
designing a meaningful trial of  hypnotherapy[13,16]. 
However, the results of  such placebo-controlled studies 
conducted so far on hypnosis for IBS[15,24] and FD, using 
a powerful double placebo of  inert pills combined with 
supportive listening, suggest that the placebo effect 
only plays a small role in the therapeutic impact of  
hypnotherapy on these conditions.
LIMITATIONS OF HYPNOTHERAPY IN 
UPPER DIGESTIVE DISEASES
Only two studies, coming from the same center, have 
tested the efficacy of  hypnotherapy in the treatment of  
upper digestive functional diseases[24,25]. These studies 
provide encouraging evidence that hypnotherapy 
is effective treatment for functional dyspepsia and 
functional chest pain of  presumed esophageal origin[19,20]. 
However, these results need to be replicated in less 
selected populations, and by independent investigators 
before a more widespread use of  hypnotherapy to treat 
upper digestive dysfunction can be recommended. 
In addition, hypnotherapy is a time consuming, labor 
intensive and costly treatment, and the number of  
health care providers trained in hypnosis is limited. 
Non-medical qualified hypnotherapists and hypnosis 
audiotapes may reduce costs, but the effectiveness of  
these alternative delivery methods on outcomes have not 
been thoroughly investigated[13,16]. Specific knowledge 
in gut-directed hypnosis is required to obtain successful 
outcomes in treating gastrointestinal disorders, and such 
training has not been widely available[13,16]. In an effort 
to overcome this problem, some centers are providing 
gut-focused hypnosis scripts to treat IBS[13]. Finally, 
skepticism by some patients and physicians about the 
use of  a psychological intervention for a gut disease may 
deter them from trying this treatment option. This may 
be particularly true for hypnosis because of  the aura of  
magic and mystery associated with it. 
CONCLUSION
Hypnosis is an altered state of  consciousness characterized 
by highly focused attention and heightened compliance 
with suggestion[1]. Clinical hypnosis can be used to treat a 
range of  complex psychological or somatic diseases, but 
this generally requires a structured form of  hypnotherapy 
intervention consisting of  several sessions[1,8]. Hypnosis 
has a long history of  applications in medicine, and is 
now formally recognized as a valuable aid for various 
medical problems. However, a limited number of  health 
professionals offer hypnotherapy for medical problems, 
and it has traditionally been hampered by misconceptions 
shrouding this psychological intervention[8,16]. Yet, 
sufficient evidence has amassed over the years to firmly 
support the effectiveness of  hypnotherapy for various 
pain problems, as well as to treat IBS, a complex and 
prevalent functional disorder of  the lower bowel[12,13,16]. 
Recently, a few studies have addressed the potential 
influence of  both single-session hypnosis and a course of  
hypnotherapy on upper digestive function and diseases 
with encouraging results. 
Hypnosis delivered on a single session by an expert 
therapist has been shown capable of  modulating gastric 
secretion and accelerating gastric emptying in healthy 
volunteers[32,36]. In addition, hypnosis has improved 
gastric emptying and epigastric sensations in severe 
functional dyspepsia[36]. Small bowel transit may also be 
influenced by hypnosis[33]. 
In the past, hypnotherapy has been used with a 
successful outcome to decrease the relapsing rate of  
peptic ulcer disease[41]. More recently, two randomized 
controlled trials have shown hypnotherapy to be a 
highly effective treatment for functional dyspepsia and 
functional chest pain of  presumed esophageal origin 
unresponsive to standard care[24,25]. In both of  these 
upper gastrointestinal diseases, clinical benefits were well 
maintained at long-term follow-ups[24,52]. However, both 
of  these studies were carried out by the same research 
team -- the Manchester group in England[16]. Additional 
well designed studies from independent investigators 
are eagerly awaited to substantiate the efficacy of  
hypnotherapy in this domain.    
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